Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab plus bevacizumab in recurrent or metastatic cervical cancer
ChiCTR2100049290Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100049290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049290.